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The accumulation of basic researches and clinical studies related to cytokine-induced killer (CIK) cells has confirmed
their safety and feasibility in treating malignant diseases. This review summarizes the available published literature
related to the biological characteristics and clinical applications of CIK cells in recent years. A number of clinical trials
with CIK cells have been implemented during the progressive phases of cancer, presenting potential widespread
applications of CIK cells for the future. Furthermore, this review briefly compares clinical applications of CIK cells
with those of other adoptive immunotherapeutic cells. However, at present, there are no uniform criteria or
large-scale preparations of CIK cells. The overall clinical response is difficult to evaluate because of the use of
autologous CIK cells. Based on these observations, several suggestions regarding uniform criteria and universal
sources for CIK cell preparations and the use of CIK cells either combined with chemotherapy or alone as a primary
strategy are briefly proposed in this review. Large-scale, controlled, grouped, and multi-center clinical trials on CIK
cell-based immunotherapy should be conducted under strict supervision. These interventions might help to
improve future clinical applications and increase the clinical curative effects of CIK cells for a broad range of
malignancies in the future.
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Cytokine-induced killer (CIK) cells are a heterogeneous
cell population that was first discovered in the 1990s
and can be generated from lymphocytes co-cultured
with an anti-CD3 antibody and many other cytokines
in vitro [1]. Numerous studies have demonstrated that
CIK cells exhibit active proliferation and potent antitu-
mor cytotoxicity against multifarious tumor cells in vitro
and in vivo [1,2]. Increasing data show that the antitu-
mor effects of CIK cells rely on a perforin-based me-
chanism and Fas-Fas ligand interactions [3,4]. CIK cells
are also not inhibited by immunosuppressive drugs [5],
which makes CIK cells an ideal candidate cell type for
cancer therapy.
Theoretically, CIK cell-based adoptive cellular immu-
notherapy (ACI) could be a curative strategy for cancer.
Abundant clinical trials on this therapeutic regimen have
been published in the past two decades, confirming its
safety and feasibility in cancer patients [6-8]. Several* Correspondence: hanwdrsw@sina.com
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stated.other clinical trials focusing on graft-versus-host disease
(GVHD) and viral infections related to this therapy have
also been conducted in recent years [9,10].
Given the ongoing investigations of CIK cell-based ACI,
this regimen has potentially widespread application pros-
pects in the clinic for most types of cancer. In addition,
several strategies to improve the clinical effects of CIK
cells have been conducted (Figure 1). For example, CIK
cells combined with traditional cancer treatments, in-
cluding surgery, chemotherapy, and radiotherapy, may
achieve the best objective responses in patients [11].
Furthermore, preconditioning chemotherapy, activated
cytokines, and specific antibodies could enhance the anti-
tumor ability of CIK cells [12-15]. Recently, attempts at
repeated CIK cell infusions have resulted in fewer adverse
events and similar clinical curative effects for some malig-
nancies in the clinic compared with genetically modified
ACI [16,17]. However, several problems, such as the
universal and massive preparation of CIK cells, must be
recognized because their resolution could improve the
clinical applications of CIK cells and better evaluatel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Figure 1 The present existing adoptive cellular immunotherapy and strategies for enhancing clinical curative effects of cytokine-induced
killer (CIK) cells. CIK cells have become the main adoptive immunotherapeutic cells because of their particular biological characteristics and have
been demonstrated to exert their therapeutic function in various malignancies except T-cell lymphoma. Additionally, numerous clinical trials have
suggested that some existing regimens using CIK cells can enhance the clinical curative effects on malignant diseases. LAK, lymphocyte-activated
killer cells; TIL, tumor-infiltrating lymphocytes; DC, dendritic cells; NK, natural killer cells; NKT, natural killer T cells; CART, chimeric antigen
receptor-modified T cells; IL, interleukin.
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peutic procedures of using CIK cells, either combined
with chemotherapy or alone as the primary strategy, will
be briefly outlined. Taken together, the status quo of CIK
cell-based ACI suggests that the use of CIK cells as an
effective clinical cancer treatment still has room for im-
provement. Further large-scale, controlled, grouped, and
multi-center CIK cell-based clinical trials are urgently
needed.
In this review, we critically summarize current re-
searches on the biological characteristics and recent cli-
nical trials of CIK cells and briefly compare the clinical
applications of CIK cells with those of other immuno-
therapeutic cells. We also present concerns on CIK cell-
based ACI drawn from these clinical trials.
Review
Biological characteristics of CIK cells
Immune phenotype of CIK cells
Up to now, intensive and strict studies on the immune
phenotype of CIK cells have been conducted. CIK cells,
which are a heterogeneous cell population, comprise
CD3+CD56+, CD3+CD56−, and CD3−CD56+ cells [18].
CD3+CD56+ cells, which are derived from CD3+CD56−
T cells, are also called natural killer T (NKT) cells and are
primarily responsible for non-major histocompatibility
complex (MHC)-restricted antitumor activity [19,20].Furthermore, this subset co-expresses CD2, T-cell recep-
tor (TCR) αβ, and CD8, but not CD16 [21]. In addition,
CD3+CD56+ cells bear the CD27+CD28− or CD27−CD28−
phenotype because they belong to terminally differentiated
T-cell populations, whereas CD3+CD56− cells are sub-
jected to early differentiation and mainly express the
CD27+CD28+ and CD62L+ phenotypes [22,23]. Mean-
while, CD3+CD56− cells also express CD4, CD8, and
TCRαβ [21,23]. CD3−CD56+ cells behave similarly to con-
ventional natural killer (NK) cells and express classical
NK-cell receptors [23]. In addition to these markers, CIK
cells express CD45RA, C-C chemokine receptor (CCR)7,
CD11a, macrophage inflammatory protein 1a, perforin,
and Fas ligand [19].
Cytokine secretion of CIK cells
Numerous studies have indicated that CIK cells express
different cytokines, with or without stimulation by tumor
cells (Table 1). In the absence of stimulation by tumor
cells, CIK cells secrete interferon (IFN)-γ and the highly
expressed cytokine receptors interleukin (IL)-2Rβ, IL-2Rγ,
IL-10Rα, and IL-10Rβ. However, the expression of cyto-
kines, including IL-2, IFN-γ, tumor necrosis factor (TNF)-α,
granulocyte-macrophage colony-stimulating factor (GM-
CSF), and IL-4, and cytokine receptors such as IL-2R, IL-
4R, IL-12R, and IL-15R, is up-regulated in CIK cells upon
stimulation by tumor cells [16,24].
Table 1 Differential cytokine and receptor expression of
cytokine-induced killer (CIK) cells upon stimulation by
tumor cells
Cytokine/receptor Secretion/expression status











IL-2, interleukin 2; IL-4, interleukin 4; IFN-γ, interferon γ; TNF-α, tumor necrosis
factor α; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-2R,
interleukin 2 receptor; IL-4R, interleukin 4 receptor; IL-10R, interleukin 10
receptor; IL-12R, interleukin 12 receptor; IL-15R, interleukin 15 receptor.
“+” indicates secreted or expressed; “-” indicates not secreted or expressed.
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The immune function-related genes of CIK cells have
also been described in recent years. A number of studies
have presented that the immune function-related genes
of CIK cells are changed under tumor cell stimulation.
For example, upon stimulation by acute myelocytic
leukemia (AML) cell lines, a CD3+CD56+ subset of CIK
cells highly express various immune function-related
genes such as IFN-γ, TNF-α, the cytokine receptor genes
IL-7R and IL-12Rβ2, the chemokine and chemokine
receptor genes C-C chemokine ligand (CCL)4, CCL5,
chemokine (C-X-C motif ) receptor (CXCR)3, and CCR1,
and the genes encoding granzyme B and caspase-1 [24].
With the exception of these genes, the expression levels
of many other genes were up-regulated and those of
7 genes were down-regulated in CIK cells stimulated by
AML cells. Furthermore, the genes encoding IFN-γ,
GM-CSF, IL-4, IL-8, IL-2Rα, IL-2Rβ, IL-4R, IL-12Rβ,
chemokines, chemokine receptors, and TNF were highly
expressed in CIK cells under stimulation by acute lym-
phoblastic leukemia (ALL) cells [22]. Based on these
findings, CIK cells may act consistently with T helper 1
and T cytotoxic 1 cell polarization upon stimulation by
tumor cells. The expression of related genes in CIK cells
seems similar even under stimulation by different tumor
cells.
Migration and homing potentials of CIK cells
Currently, the migration and homing of CIK cells are
being investigated. To date, more and more evidence
from animal models has indicated that CIK cells, similar
to conventional T cells, can migrate to tumors, tumor-draining lymph nodes, and spleen tissues [25,26]. The
distribution and order of flow for CIK cells were related
to the immune properties of the cells, the blood supply,
and the expression of certain specific chemokines and
chemokine receptors for the tumor. The detailed mecha-
nism and efficacy of CIK cell trafficking might involve
(1) the up-regulation of specific receptors or ligands on
the tumor or tumor-draining lymph nodes to promote
the homing, adhesion, and infiltration of CIK cells
[25,26] and (2) the chemokines, chemokine receptors,
selectins, and adhesion molecules expressed on CIK cells
that are involved in the migration of CIK cells across the
endothelium [23,25,26]. On the contrary, CIK cells in-
filtrate normal target tissues to a much smaller extent or
transiently for a longer time [25]. This result was con-
firmed by another animal study. CIK cells are effective
against Fas ligand-positive malignant cells and cells with
multidrug resistance. It has been observed that a popula-
tion of CIK cells migrated to tumor sites by 72 h after
infusion and remained detectable at these sites for an
additional 9 days. Meanwhile, transplanted tumor cells
in mice could be significantly destroyed by these CIK
cells [27].
Cytotoxic activities of CIK cells
Thus far, numerous studies have demonstrated that CIK
cells have potent cytotoxic activities against various tu-
mors such as human leukemia, ovarian cancer, lung can-
cer, liver cancer, cervical cancer, and colorectal cancer;
among CIK cells, CD3+CD56+ cells have the most potent
MHC-unrestricted cytolytic effect [19,28]. The antitumor
mechanisms of CIK cells include (1) effector cell-target
cell contacts through binding of the surface adhesion mol-
ecule leukocyte function-associated antigen-1 (LFA-1) on
CIK cells to LFA-1 ligands expressed on most susceptible
tumor cells, thereby leading to cytotoxicity against tumor
cells [3,29]; (2) the cell signaling pathway involving the
binding and activity of NK-cell receptors to their ligands,
which are highly expressed on tumor cells, resulting in
CIK cell activation that leads to degranulation and cyto-
toxicity against tumor cells [30]; and (3) the induction of
tumor cell apoptosis by Fas ligand via the Fas signaling
pathway [19]. In addition, applications in an animal model
suggested that in vivo antitumor effects against various
hematopoietic and solid tumors occurred after the infu-
sion of CIK cells [19,27]. A preclinical study reported that
the survival of severe combined immunodeficient mice
injected with human lymphoma cells could be signifi-
cantly prolonged after receiving CIK cell infusion [19].
Clinical applications of CIK cells in disease therapy
The therapeutic potential of CIK cells as a potential
adjuvant therapy for cancer has already been well re-
cognized. A number of studies have indicated that
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feasible for cancer patients [6,7,31]. The antitumor effects
of CIK cells have been observed on both hematologic ma-
lignancies and many solid tumors [6,7,16,17]. In addition,
the anti-virus and anti-GVHD potentials of CIK cells
could be extensively used for clinical applications [9,10].
At present, the clinical effect of CIK cells has been
supported by an increasing number of clinical trials on
various types of tumors. A total number of 40 registered
clinical trials involving different hematologic malig-
nancies and solid tumors can be found on the website
ClinicalTrials.gov (http://www.clinicaltrials.gov) (Table 2).
More importantly, CIK cells can be successfully gene-
rated from patients with various malignancies, regardless
of whether they have received chemotherapy or other
treatments. Below, we rigorously summarize recent cli-
nical trials with CIK cells for various disorders.
Safety in patients with malignancies after receiving CIK cell
infusion
Safety is the greatest advantage of the adoptive infusion
of CIK cells in patients with malignant diseases. In re-
cent years, an increasing number of animal studies have
indicated that a regimen involving the adoptive infusion
of CIK cells confers considerable antitumor effect with-
out severe adverse events in animals with malignancies
[25,32,33]. For example, no infusion-related acute and
delayed toxicities developed after human CIK cell in-
fusion in nude mice bearing the human colorectal
cancer cell line SW1116 [32]. In a murine lymphoma-
inoculated H-2d recipient mouse model transplanted
with hematopoietic stem cells from H-2b donor mice, no
or minimal GVHD developed after CIK cells expanded
from donors were infused [33]. Moreover, Nishimura
et al. [25] infused lethally irradiated BALB/c mice with
allogeneic CIK cells generated from FVB mice. After re-
ceiving increasing doses of CIK cells, these mice showed
minimal signs of GVHD and mild weight loss, and all
mice survived.
On the basis of animal studies, a large number of cli-
nical trials have indicated that adverse events seldom oc-
curred after the infusion of CIK cells; most of the adverse
events were minor, including mild fever, chills, fatigue,
and GVHD. In a phase I clinical trial, 3 out of 10 patients
developed fevers that spontaneously resolved after receiv-
ing autologous CIK cells electroporated with the IL-2 gene
[8]. The fever was likely due to the transfected IL-2 gene.
Very recently, the same group summarized adverse events
in 206 patients with various hematologic malignancies en-
rolled in 17 clinical trials [34]. After receiving autologous
or allogeneic CIK cells, minimal adverse events, such as
mild fever (37.5°C-40°C), transient ventricular arrhyth-
mias, chills, fatigue, and GVHD, developed and were easily
treated with symptomatic regimens [34]. Chung et al. [35]reported that only grade 3 toxicities, including general
weakness in 2 patients and thrombocytopenia in 1 patient,
occurred after treating 20 advanced pancreatic cancer pa-
tients with autologous CIK cells. In another phase I study,
autologous CIK cells were given to 10 patients with renal
cell carcinoma after radical nephrectomy [36]. Adverse
events included mild arthralgia, laryngeal edema, fatigue,
and low-grade fever and developed in only 3 patients
during the course of CIK cell infusion; these events were
either resolved without intervention or treated with symp-
tomatic treatments [36].
Feasibility of treating malignant diseases with CIK cells
More excitingly, over the last few decades, many clinical
trials have indicated that the adoptive infusion of CIK cells
is feasible for patients with malignancies. The first clinical
trial using CIK cells modified with the IL-2 gene for the
treatment of 10 patients with metastatic renal carcinoma,
colorectal cancer, and lymphoma reported that 1 patient
acquired a complete remission [8]. In addition, the same
group summarized the overall benefits in 206 patients
with various hematologic malignancies who had recently
received autologous or allogeneic CIK cells and were en-
rolled in 17 clinical trials [34]. More than 40% of the pa-
tients attained overall disease control (complete remission
in 58 patients, partial remission in 15 patients, and stable
disease in 11 patients) after the infusion of CIK cells. In
our group, we used autologous CIK cells to treat 2 pa-
tients with recurrent or refractory AML [16]. After 4 in-
fusions within 4 months, the leukemia burden in the
peripheral blood of 1 patient was dramatically decreased.
Aside from hematologic malignancies, the use of CIK cells
has also been explored in clinical trials as a treatment for
various solid tumors. In one report, 79 patients with stage
III non-small cell lung cancer who were treated with
dendritic cell-CIK cell infusions and chemotherapy had a
longer median disease-free survival and a lower 3-year
cumulative recurrence rate than the patients who were
treated with chemotherapy alone (28 months vs. 22 months;
47.37% vs. 76.92%) [37]. In another study, 156 patients with
gastric cancer after operations were divided into two
groups: 75 received CIK cell infusions plus chemotherapy,
and 81 underwent chemotherapy alone [7]. The 2- and 5-
year survival rates were higher in the combination treat-
ment group than in the chemotherapy group (73.5% vs.
52.6%; 40.4% vs. 23.9%). Based on the above-mentioned
data, CIK cell-based ACI is a highly feasible regimen for
tumor therapy in the clinic. Especially in combination
with other treatments, the clinical curative effect of CIK
cell-based ACI becomes more prominent.
CIK cells in viral infections
Current studies have indicated that hepatitis B virus
(HBV) replication in hepatocellular carcinoma (HCC)
Table 2 Current status of clinical trials of CIK cells
Target disease Registered trial Phase Combined treatment Enrolled patients (cases)
Lung cancer NCT01498055 II/III None 120
NCT01631357 II/III Chemotherapy 200
Small cell lung cancer NCT01592422 II Best supportive care 60
NCT01481259 II/III Chemotherapy 120
Non-small cell lung cancer NCT01902875 Undefined Chemotherapy 100
NCT01871480 II Gefitinib 50
Hepatocellular carcinoma NCT01821482 II DC 100
NCT01758679 IV Chemotherapy 120
NCT01749865 III None 200
NCT00769106 III None 200
Renal cell carcinoma NCT01924156 I/II Adenovirus-transfected autologous DC 30
NCT00862303 I/II DC + cytokines 100
NCT01240005 I/II None 30
Nasopharyngeal carcinoma NCT01655628 II Chemotherapy 40
NCT01821495 II DC 100
Esophageal carcinoma NCT01691625 Undefined Chemoradiotherapy + DC 50
NCT01691664 Undefined Radiotherapy + DC 40
Colorectal cancer NCT01839539 II DC 60
NCT02202928 II Chemoradiotherapy + DC 60
NCT01929499 II None 210
Gastric cancer NCT02215837 II DC 40
NCT01783951 I/II Chemotherapy + DC 70
Pancreatic cancer NCT01781520 I/II Chemotherapy + DC 30
Cholangiocarcinoma NCT01868490 I/II None 13
High-risk soft tissue sarcoma NCT01898663 I/II Adenovirus-transfected autologous DC 30
Malignant glioma NCT01235845 I/II DC 30
Triple negative breast neoplasms NCT01395056 Undefined Chemotherapy + DC 50
Solid tumor NCT01914263 I None 40
Solid tumor and B-cell lymphoma NCT01799083 I/II Chemotherapy 100
Hematologic malignancies NCT00460694 I/II None 20
NCT00477035 I/II Chemotherapy 22
NCT01186809 II None 39
NCT00186342 Undefined Ablative allo-HCT 120
Multiple myeloma NCT00185757 I None 20
Acute leukemia NCT01956630 I/II Genetically modified DC 25
Chronic myeloid leukemia NCT00815321 II None 11
Acute myeloid leukemia and
myelodysplastic syndrome
NCT00394381 I/II None 17
Myelodysplastic syndrome NCT01392989 II Chemotherapy 21
Lymphoma NCT01828008 Undefined None 20
Malignant tumor NCT01884168 Undefined DC 30
These data were searched on 15 July 2014 from the website ClinicalTrials.gov (http://www.clinicaltrials.gov). The key word “cytokine-induced killer cells” was used.
DC, dendritic cells; HCT, hematopoietic cell transplantation.
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induced chronic hepatitis B is a major threat to human
health worldwide, and HBV infection also increases the
risk of developing HCC [38]. However, less dramatic
treatments have been rather effective in recent years.
Still, various evidence indicates that the CD3+CD56+
subset of CIK cells, which are referred to as NKT cells
and play an important role in anti-viral infections, might
be the main driver of the anti-HBV infection effect
[19,20,39,40]. In brief, these issues make it important to
obtain definitive evidence of the efficacy of CIK cells for
treating viral infections.
CIK cells in GVHD
Allogeneic transplantation is a common treatment for
hematopoietic malignancies, and GVHD, a life-threatening
symptom of allogeneic transplantation, is a main cause of
transplantation-related death [41,42]. Because of the ex-
tensive research and application of CIK cell therapy for
hemotologic diseases, we separately listed and discussed
the relationship between CIK cells and GVHD. Moreover,
traditional immunosuppressants frequently fail to sup-
press GVHD; thus, a safe and effective approach is needed
to better treat patients with GVHD. Recent studies have
demonstrated that NKT cells can suppress transplant re-
jection [39,40]. Therefore, the anti-GVHD properties of
CIK cells are similar to those of NKT cells because of CD3
+CD56+ CIK cells, here referred to as NKT cells. Although
hematopoietic stem cell transplantation (HSCT) is an ef-
fective treatment for hematologic malignancies, allogeneic
immune activation might promote GVHD [43,44]. With
the transplantation of CIK cells after HSCT, the risk of
GVHD decreases [9]. Based on the information above,
CIK cell therapy is regarded as an effective immunosup-
pressant of GVHD, which often occurs following allogen-
eic transplantation.
Comparison of clinical applications of CIK cells and other
adoptive immunotherapeutic cells
Over the last few decades, the idea of ACI for cancer
has been slowly becoming a reality. Adoptive immuno-
therapeutic cells have mainly included tumor-infiltrating
lymphocytes (TIL), lymphokine-activated killer (LAK)
cells, CIK cells, and chimeric antigen receptor-modified
T (CART) cells. Studies demonstrated that ACI with TIL
cells for melanoma patients achieved more exciting
clinical benefits based on the in vitro selection of tumor-
specific T cell lines and MHC-restricted antitumor func-
tion [45,46]. Nevertheless, the extremely low number of
TIL cells or tumor cells that lost the expression of a spe-
cific antigen or MHC molecule render TIL cell-based
ACI procedures not suitable for cancer patients [26].
LAK cells were used for the first prototype of ACI; how-
ever, LAK cells expanded insufficiently ex vivo. The lowcytolytic effects of LAK cells in vivo hampered their cli-
nical applications as a cancer therapy and have led to
few successful clinical trials [47-49]. Based on LAK cells,
CIK cells were generated and shown to have a sub-
stantial increase in cytotoxic effect and proliferative re-
sponse, which has recently been widely applied to treat
tumors in the clinic [1]. Compared with traditional im-
munotherapeutic cells, CART cells can specifically target
tumor cells and persistently proliferate, survive, and dis-
play antitumor abilities [50,51]. The one-time infusion of
these cells may decrease the infusion frequencies and
cell numbers, further making CART cells an ideal and
novel candidate cell type for cancer therapy. To sum-
marize the above findings, CIK cell-based ACI is a can-
cer treatment that can be used in some cancers with
unclear tumor target genes, and repeated infusions of
CIK cells or CIK cell infusion in combination with other
therapeutic regimens may achieve unexpected clinical ef-
fects. Moreover, CART cell-based ACI is more suitable
for cancers with clear tumor target genes; this treatment
could possibly achieve a cure.
Importantly, successful ACI is based on a detailed esti-
mation of a particular disease, including tumor eva-
luation, tumor incidence, tumor growth characteristics,
and a portfolio of alternative treatment strategies [52].
In accordance with the biological characteristics of these
immunotherapeutic cells, CIK cells are more suitable for
tumors with no specific tumor antigen, small lesions,
slow proliferation, early disease stages, and alternative
treatments. In recent years, a number of clinical studies
have indicated that repeated CIK cell infusions could be
well tolerated and produce good clinical outcomes for
patients with hematologic malignancies such as AML
and diffuse large B-cell lymphoma [16,17]. This treat-
ment is able to overcome the defect that a single infu-
sion cannot offer a sufficient or effective number of cells
to eradicate tumor cells. This is because CIK cells belong
to a subpopulation of terminally differentiated effector
T cells that have restricted survival in vivo [53]. In
addition, using CIK cell-based ACI to consolidate the-
rapy is very advantageous for patients to obtain overall
disease control as a clinical outcome with no or minimal
adverse events.
Potential concerns of CIK cells in the clinic
Uniform criterion and large scale of CIK cell preparations
At present, CIK cells can be easily generated from
various sources, mainly including autologous peripheral
blood and bone marrow [54]. The infusion of these cells
is well tolerated and does not cause severe adverse
events, such as fever, myalgia, flu-like symptoms, and
fatigue. Further, this strategy can be easily applied in
advanced and/or metastatic malignant diseases [55,56].
Many clinical trials with CIK cell-based ACI have
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Nevertheless, the prognosis and clinical curative effects
are difficult to assess because CIK cells were prepared
from autologous sources among different cancer pa-
tients. In addition, the adoptive infusion of allogeneic
CIK cells could cause GVHD despite their weak allor-
eactivity and low GVHD potential in vivo. Therefore,
searching for universal sources for CIK cell preparation
may be a better approach to resolving these problems.
Compared with unrelated donor peripheral blood and
bone marrow, umbilical cord blood (UCB) has several ad-
vantages, including easy acquisition, rapid availability, and
low to no risk of adverse events such as GVHD [57]. More
recently, some studies have indicated that CIK cells pre-
pared from UCB are suitable for immunotherapy against
both malignant and nonmalignant disorders [11,58].
UCB-derived CIK (UCB-CIK) cells have similar biological
characteristics to traditional CIK cells obtained from per-
ipheral blood [11]. Moreover, some clinical studies have
demonstrated that treating malignancies with UCB-CIK
cells shows promising efficacy with negligible adverse
events, such as transient fever, most of which disappeared
without pharmacologic intervention [11,58]. Because of
this finding, this treatment strategy with UCB-CIK cells
may represent a safe and feasible approach to treat pa-
tients with various malignancies. Furthermore, some stu-
dies have indicated that universal T-cell products could be
generated from allogeneic donors based on the knock-
down of the human leukocyte antigen genes to avoid NK
cell-mediated recognition and lysis [59,60]. In addition,
hematopoietic stem cells and other precursor cells have
been confirmed as potentially being among the starting
cell types of T-cell products [61-63]. Accordingly, treat-
ment with CIK cells generated from these sources may
also be ideal and safe for cancer patients because of the
lower alloreactivity of these cells. In conclusion, the infu-
sion of allogeneic CIK cells generated from the sources
mentioned above might not trigger alloreactivity in vivo,
although these cells were prepared from an unrelated
donor. The prognosis and clinical curative effects could be
easily evaluated under that CIK cells were generated from
universal sources.
However, there are many studies reporting that CIK
cells can be generated under different culturing proce-
dures, such as activation and proliferation with IFN-γ,
anti-CD3 antibody, and IL-2, as well as additional acti-
vated cytokines [1,50]. However, the similar antitumor
ability, immune phenotypes, cytokine secretions, and an-
titumor patterns of these CIK cells may be different.
Therefore, the preparation of universal CIK cell products
under uniform culturing criteria would likely enhance
the uniformity of the biological characteristics of the
cells to allow for better evaluation of the clinical curative
effects. Using streamlined and centralized manufacturingof CIK cells, including large-scale preparations and cryo-
preservation, these cells could probably be commer-
cialized anywhere, thereby increasing convenience and
flexibility for cancer patients.
Cancer therapy with CIK cells combined with chemotherapy
or alone as a primary strategy
For advanced malignant diseases, the efficacy of chemo-
therapy is often low because of the resistance of tumor
cells against antitumor drugs. Therefore, new antitumor
approaches to overcome and/or ameliorate this resistance
to chemotherapeutic drugs in cancer patients are urgently
needed. Recently, studies have indicated that immunothe-
rapy with CIK cells may promisingly overcome chemo-
therapy resistance by stimulating the immune system and
enhancing its antitumor abilities [64,65]. Nevertheless,
CIK cell-based ACI is often regarded simply as a comple-
mentary treatment for cancer therapy by certain clinical
researchers and patients and may only be used to treat
cancer patients if their state is otherwise incurable. Exci-
tingly, abundant clinical researches have indicated that
CIK cell-based ACI has potential beneficial clinical effects
for patients with refractory and recurrent malignancies.
Because of those findings, combining the therapeutic regi-
mens of CIK cells with chemotherapy or using them alone
as a primary strategy may result in better clinical benefits
for cancer patients. In the future, several tasks should be
urgently addressed, including the following aims: (1) to
establish the benefits of using CIK cells as a primary strat-
egy, combined with chemotherapeutic drugs or alone;
(2) to observe the clinical curative effects and adverse
events in the processing of these regimens; and (3) to
analyze and compare these effects with the clinical bene-
fits of traditional chemotherapy.
Conclusions
Considering the preclinical and clinical studies together,
CIK cell-based ACI has demonstrated considerable bene-
fits in various malignancies. The significant outputs do ap-
pear promising for clinical curative effects. However,
many of the problems mentioned above must be resolved
to acquire a better clinical curative effect of cancer treat-
ment using CIK cells. Therefore, it is of particular im-
portance to implement large-scale, controlled, grouped,
and multi-center clinical trials to enhance the therapeutic
effects of CIK cell-based ACI.
These interventions might make CIK cell-based ACI
an effective and routine therapy for cancer. In conclu-
sion, CIK cell-based ACI has significant potential to
improve clinical tumor therapy and to ameliorate the
quality of life in patients with various malignancies.
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